Home › Companies › Royalty Pharma plc › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Royalty Pharma plc’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2026: 18 items on Royalty Pharma plc’s Form 8-K, filed June 4, 2026: 18 passed (calculated).
Notable dissent: 1 director (11.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Royalty Pharma plc in the interactive database Compare manager voting policies
These tallies are Royalty Pharma plc’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Pablo Legorreta | 458,242,360 | 29,448,236 | 168,578 | -- | 20,320,929 | 94% | Passed (calculated) | — |
| Elect Director: Ted Love, M.D. | 464,556,053 | 23,135,217 | 167,904 | -- | 20,320,929 | 95% | Passed (calculated) | — |
| Elect Director: Bonnie Bassler, Ph.D. | 486,078,663 | 1,615,471 | 165,040 | -- | 20,320,929 | 99.7% | Passed (calculated) | — |
| Elect Director: Vlad Coric, M.D. | 433,218,530 | 54,472,087 | 168,557 | -- | 20,320,929 | 89% | Passed (calculated) | — |
| Elect Director: Catherine Engelbert | 485,200,369 | 2,492,809 | 165,996 | -- | 20,320,929 | 99.5% | Passed (calculated) | — |
| Elect Director: Carole Ho, M.D. | 487,136,029 | 557,922 | 165,223 | -- | 20,320,929 | 99.9% | Passed (calculated) | — |
| Elect Director: David Hodgson | 479,933,527 | 7,733,381 | 192,266 | -- | 20,320,929 | 98% | Passed (calculated) | — |
| Elect Director: Gregory Norden | 481,576,664 | 6,090,949 | 191,561 | -- | 20,320,929 | 99% | Passed (calculated) | — |
| Elect Director: Elizabeth Weatherman | 487,564,658 | 128,998 | 165,518 | -- | 20,320,929 | 99.9% | Passed (calculated) | — |
| 2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers | 476,044,602 | 11,067,486 | 747,086 | -- | 20,320,929 | 98% | Passed (calculated) | — |
| 3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm | 506,307,829 | 832,217 | 1,040,057 | -- | -- | 99.8% | Passed (calculated) | — |
| 4. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports, including the directors' report, the strategic report, the directors' remuneration report and the auditors' report for the fiscal year ended Dece | 487,151,335 | 98,040 | 609,799 | -- | 20,320,929 | 99.9% | Passed (calculated) | — |
| 5. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts | 478,165,378 | 8,935,552 | 758,244 | -- | 20,320,929 | 98% | Passed (calculated) | — |
| 6. To re-appoint Ernst & Young as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders | 506,752,136 | 384,952 | 1,043,015 | -- | -- | 99.9% | Passed (calculated) | — |
| 7. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor | 487,092,662 | 575,800 | 190,712 | -- | 20,320,929 | 99.9% | Passed (calculated) | — |
| 8. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares | 474,475,427 | 12,499,628 | 884,119 | -- | 20,320,929 | 97% | Passed (calculated) | — |
| 9. To authorize the Board of Directors to allot shares | 469,111,384 | 18,568,396 | 179,394 | -- | 20,320,929 | 96% | Passed (calculated) | — |
| 10. To authorize the Board of Directors to allot shares without rights of pre-emption | 445,653,078 | 42,016,406 | 189,690 | -- | 20,320,929 | 91% | Passed (calculated) | — |
Source: Royalty Pharma plc, Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
564 asset managers disclosed a vote on at least one Royalty Pharma plc item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Royalty Pharma plc’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Prior year: 95.0% for (May 12, 2025 meeting) ▼ 1.0 pts
Description as filed by funds: Election of Directors: Pablo Legorreta
Royalty Pharma plc’s own tally for this item (“Elect Director: Pablo Legorreta”): 458,242,360 for, 29,448,236 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 124,207,914 for, 451,760 against, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,904 | 75 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Prior year: 92.9% for (May 12, 2025 meeting) ▲ 2.4 pts
Description as filed by funds: Election of Directors: Ted Love, M.D.
Royalty Pharma plc’s own tally for this item (“Elect Director: Ted Love, M.D.”): 464,556,053 for, 23,135,217 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 123,287,020 for, 1,372,654 against, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,923,905 | 9,032 | 0 | 0 | For |
| Vanguard | 8,258,234 | 22,745 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 0 | 596,935 | 0 | 0 | Against |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Prior year: 98.9% for (May 12, 2025 meeting) ▲ 0.8 pts
Description as filed by funds: Election of Directors: Bonnie Bassler, Ph.D.
Royalty Pharma plc’s own tally for this item (“Elect Director: Bonnie Bassler, Ph.D.”): 486,078,663 for, 1,615,471 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 124,639,672 for, 2 against, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,977 | 2 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Prior year: 99.4% for (May 12, 2025 meeting) ▼ 10.6 pts
Description as filed by funds: Election of Directors: Vlad Coric, M.D.
Royalty Pharma plc’s own tally for this item (“Elect Director: Vlad Coric, M.D.”): 433,218,530 for, 54,472,087 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 116,134,376 for, 8,505,297 against, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 6,027,226 | 2,253,752 | 0 | 0 | Mixed |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,740 | 2,937,710 | 0 | 0 | Against |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 0 | 528,307 | 0 | 0 | Against |
| Equitable | 360,849 | 138,721 | 0 | 0 | Mixed |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Prior year: 99.2% for (May 12, 2025 meeting) ▲ 0.3 pts
Description as filed by funds: Election of Directors: Catherine Engelbert
Royalty Pharma plc’s own tally for this item (“Elect Director: Catherine Engelbert”): 485,200,369 for, 2,492,809 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 124,648,668 for, 6 against, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,973 | 6 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Carole Ho, M.D.
Royalty Pharma plc’s own tally for this item (“Elect Director: Carole Ho, M.D.”): 487,136,029 for, 557,922 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 124,648,672 for, 2 against, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,977 | 2 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 97.6% for (May 12, 2025 meeting) ▲ 0.8 pts
Description as filed by funds: Election of Directors: David Hodgson
Royalty Pharma plc’s own tally for this item (“Elect Director: David Hodgson”): 479,933,527 for, 7,733,381 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 124,408,287 for, 240,385 against, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,961 | 16 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 97.5% for (May 12, 2025 meeting) ▲ 1.2 pts
Description as filed by funds: Election of Directors: Gregory Norden
Royalty Pharma plc’s own tally for this item (“Elect Director: Gregory Norden”): 481,576,664 for, 6,090,949 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 124,625,561 for, 23,113 against, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,963 | 16 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Elizabeth Weatherman
Royalty Pharma plc’s own tally for this item (“Elect Director: Elizabeth Weatherman”): 487,564,658 for, 128,998 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 124,625,577 for, 23,097 against, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,979 | 0 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Approve the terms of the agreements and counterparties pursuant to which we may purchase our Class A ordinary shares.
Royalty Pharma plc’s own tally for this item (“8. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares”): 474,475,427 for, 12,499,628 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 108 asset managers below reported 124,743,850 for, 35 against, 20,002 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,941 | 35 | 2 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Authorize the Board to allot shares without rights of pre-emption (special resolution).
Royalty Pharma plc’s own tally for this item (“10. To authorize the Board of Directors to allot shares without rights of pre-emption”): 445,653,078 for, 42,016,406 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 108 asset managers below reported 122,896,845 for, 1,867,042 against, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 6,810,309 | 1,470,669 | 0 | 0 | Mixed |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% of fund votes cast · no official result
The 108 asset managers below reported 124,582,564 for, 181,323 against, 373 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,930 | 48 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).
Combines 11 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 91.6% for (May 12, 2025 meeting) ▲ 6.1 pts
Description as filed by funds: A non-binding advisory vote to approve executive compensation.
Royalty Pharma plc’s own tally for this item (“2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 476,044,602 for, 11,067,486 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,952 | 25 | 2 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 524,331 | 3,976 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Fund voting reports, all 107 managers: 124,302,283 for, 370,466 against, 139,849 abstained, 373 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 44,668,043 | 0 | 0 | 0 | For |
| Morgan Stanley | 35,316,977 | 0 | 0 | 0 | For |
| Fidelity | 18,924,572 | 0 | 0 | 0 | For |
| BlackRock | 18,369,446 | 0 | 0 | 0 | For |
| Swedbank Robur Fonder AB | 11,586,693 | 0 | 0 | 0 | For |
| State Street | 8,342,985 | 10,152 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 7,872,174 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 6,580,633 | 0 | 0 | 0 | For |
| Caledonia (Private) Investments Pty Ltd | 5,051,550 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 4,663,534 | 0 | 0 | 0 | For |
| Victory Capital | 3,867,577 | 0 | 0 | 0 | For |
| Invesco | 3,607,096 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD & CO | 3,585,063 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD & CO LTD | 3,315,813 | 0 | 0 | 0 | For |
| Vanguard | 3,292,401 | 0 | 0 | 0 | For |
| Charles Schwab | 3,032,105 | 0 | 0 | 0 | For |
| Amundi | 566,094 | 2,108,226 | 0 | 0 | Mixed |
| Northern Trust | 2,527,141 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,384,371 | 0 | 0 | 0 | For |
| NEW SOUTH CAPITAL MANAGEMENT INC | 2,376,063 | 0 | 0 | 0 | For |
| Regal Partners Ltd | 2,307,376 | 0 | 0 | 0 | For |
| Dorsey Asset Management, LLC | 2,276,570 | 0 | 0 | 0 | For |
| London LGPS CIV Ltd | 2,204,941 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 2,109,289 | 12,160 | 0 | 0 | For |
| AQR | 1,925,686 | 0 | 0 | 0 | For |
Institutional-manager reports, all 485 managers: 253,179,041 for, 7,856,569 against, 1,536,477 abstained, 22,438 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Approve on a non-binding advisory basis our U.K. directors' remuneration report for the fiscal year ended December 31, 2025.
Royalty Pharma plc’s own tally for this item (“5. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts”): 478,165,378 for, 8,935,552 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,958 | 18 | 2 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Fund voting reports, all 105 managers: 124,236,183 for, 366,483 against, 140,349 abstained, 373 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 18,369,446 | 0 | 0 | 0 | For |
| Caledonia (Private) Investments Pty Ltd | 5,051,550 | 0 | 0 | 0 | For |
| Vident Advisory, LLC | 14,802 | 0 | 0 | 0 | For |
| Ethic Inc. | 0 | 4,232 | 100 | 0 | Against |
| Argent Trust Co | 2,842 | 0 | 0 | 0 | For |
| R. W. Roge & Company, Inc. | 1,000 | 0 | 0 | 0 | For |
| Formidable Asset Management, LLC | 721 | 0 | 0 | 0 | For |
| Keel Point, LLC | 648 | 0 | 0 | 0 | For |
| Beacon Bank & Trust | 641 | 0 | 0 | 0 | For |
| Smithfield Trust Co | 603 | 0 | 0 | 0 | For |
| Midwest Trust Co | 500 | 0 | 0 | 0 | For |
| Haverford Trust Co | 144 | 0 | 0 | 0 | For |
| Glenview Trust Co | 122 | 0 | 0 | 0 | For |
| Pinnacle Financial Partners, Inc. | 121 | 0 | 0 | 0 | For |
| Roberts Wealth Advisors, LLC | 3 | 0 | 0 | 0 | For |
| Ariadne Wealth Management, LP | 1 | 0 | 0 | 0 | For |
Institutional-manager reports, all 16 managers: 23,443,144 for, 4,232 against, 100 abstained.
Combines 4 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Prior year: 100.0% for (May 12, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.
Royalty Pharma plc’s own tally for this item (“3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm”): 506,307,829 for, 832,217 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 124,639,172 for, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,977 | 0 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next general meeting at which the U.K. annual report and accounts are presented to shareholders.
Royalty Pharma plc’s own tally for this item (“6. To re-appoint Ernst & Young as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report an”): 506,752,136 for, 384,952 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 124,639,172 for, 2 against, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,977 | 2 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory auditor.
Royalty Pharma plc’s own tally for this item (“7. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor”): 487,092,662 for, 575,800 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 124,658,674 for, 139,847 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,979 | 0 | 0 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. All 109 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports for the fiscal year ended December 31, 2025.
Royalty Pharma plc’s own tally for this item (“4. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports, including the directors' report, the strategic report, the directors' remuneration report and the auditor”): 487,151,335 for, 98,040 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 108 asset managers below reported 124,604,539 for, 139,849 abstained, 373 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 37,466,076 | 0 | 0 | 0 | For |
| Fidelity | 23,338,697 | 0 | 0 | 0 | For |
| Morgan Stanley | 9,932,937 | 0 | 0 | 0 | For |
| Vanguard | 8,280,977 | 0 | 2 | 0 | For |
| BlackRock | 7,765,898 | 0 | 0 | 0 | For |
| Victory Capital | 6,902,683 | 0 | 0 | 0 | For |
| Invesco | 3,090,537 | 0 | 0 | 0 | For |
| Charles Schwab | 2,940,450 | 0 | 0 | 0 | For |
| Transamerica | 2,667,195 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 2,500,000 | 0 | 0 | 0 | For |
| Brighthouse | 1,900,841 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,410,745 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,073,575 | 0 | 0 | 0 | For |
| Goldman Sachs | 922,117 | 0 | 0 | 0 | For |
| First Trust | 757,711 | 0 | 0 | 0 | For |
| Pacific Life | 738,489 | 0 | 0 | 0 | For |
| TIAA | 727,951 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 681,715 | 0 | 0 | 0 | For |
| State Street | 596,935 | 0 | 0 | 0 | For |
| JPMorgan | 593,735 | 0 | 0 | 0 | For |
| AQR | 559,517 | 0 | 0 | 0 | For |
| SEI | 528,307 | 0 | 0 | 0 | For |
| Equitable | 499,570 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 493,508 | 0 | 0 | 0 | For |
| Thrivent | 490,731 | 0 | 0 | 0 | For |
Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 2 items from the meeting of May 12, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 436,790,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 8.58% |
| 2 | Fidelity | 5.34% |
| 3 | Morgan Stanley | 2.27% |
| 4 | Vanguard | 1.90% |
| 5 | BlackRock | 1.78% |
| 6 | Victory Capital | 1.58% |
| 7 | Invesco | 0.71% |
| 8 | Charles Schwab | 0.67% |
| 9 | Transamerica | 0.61% |
| 10 | Advisor Managed Portfolios | 0.57% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 10.23% |
| 2 | Morgan Stanley | 8.09% |
| 3 | Fidelity | 4.33% |
| 4 | BlackRock | 4.21% |
| 5 | Swedbank Robur Fonder AB | 2.65% |
| 6 | State Street | 1.91% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.80% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.51% |
| 9 | Caledonia (Private) Investments Pty Ltd | 1.16% |
| 10 | BAILLIE GIFFORD OVERSEAS LTD | 1.07% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Legorreta G. Pablo | 101,785,843 | 23.30% | Schedule 13D, filed August 17, 2026 |
| RPI US Partners 2019, LP | 98,287,272 | 22.50% | Proxy statement (DEF 14A), proxy filed April 10, 2026 |
| Morgan Stanley | 38,907,011 | 8.91% | Proxy statement (DEF 14A), proxy filed April 10, 2026 |
| Capital International Investors | 32,745,526 | 7.50% | Proxy statement (DEF 14A), proxy filed April 10, 2026 |
| FMR LLC | 27,900,714 | 6.39% | Proxy statement (DEF 14A), proxy filed April 10, 2026 |
| BlackRock | 25,907,745 | 5.93% | Form 13F, quarter ended March 31, 2026 |
| FMR (Fidelity) | 25,152,242 | 5.76% | Form 13F, quarter ended March 31, 2026 |
| R & H Trust Co. (Guernsey) Limited | 24,223,082 | 5.55% | Schedule 13D, filed February 20, 2026 |
| PL RPH Holdings, LLC | 13,356,742 | 3.06% | Proxy statement (DEF 14A), proxy filed April 10, 2026 |
| State Street | 10,989,851 | 2.52% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 436,790,000 shares outstanding, as reported by Royalty Pharma plc on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Royalty Pharma plc's shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 564 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 9,527 separate fund positions. Their filings are grouped here into 18 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — A non-binding advisory vote to approve executive compensation. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Royalty Pharma plc's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Royalty Pharma plc’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Royalty Pharma plc proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Royalty Pharma (RPRX) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/royalty-pharma-plc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.